Compiled By Travis Hessman Indianapolis-based Eli Lilly and Co. has announced plans to build a $250 million biotechnology manufacturing facility in Puerto Rico. The fourth Lilly site in the area, the facility initially will manufacture Humalog, used worldwide for the treatment of diabetes. The pharmaceutical company cites positive economic incentives, the availability of a skilled work force, and the proven results of its current employees and operations as motivations to build the project in Puerto Rico. Also, Eli Lilly says forecasts indicate continuing strong demand for its product due to an accelerating prevalence of diabetes. "The new facility will be an important step to ensuring Lilly is prepared to satisfy the market demand," notes Pedro P. Granadillo, senior vice president, Eli Lilly and Co. Construction of the new facility is expected to begin later this year, with it becoming fully operational in 2005. The new facility will hire 300 workers over the next three years, increasing Lilly's local work force by 30%.